Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site

Renal Cell Cancer


Ilya Tsimafeyeu


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


I. Tsimafeyeu1, R. Zukov2, L. Demidov3, P. Borisov4, V. Kuznetsov5, V. Leonenko5, A. Bondarenko6, K. Zakurdaeva7, Y. Tishova8

Author affiliations

  • 1 Moscow Office, Kidney Cancer Research Bureau, 125635 - Moscow/RU
  • 2 Dept. Of Oncourology, A.I. Kryzhanovsky Krasnoyarsk Cancer Center, Krasnoyarsk/RU
  • 3 Dept. Of Biotherapy, N.N. Blokhin National Medical Research Center of Oncology, 115478 - Moscow/RU
  • 4 Outpatient Department, City Clinical Oncology Center, St. Petersburg/RU
  • 5 Tuchkovo Branch, Stolichnaya Diagnostica Clinic, Tuchkovo/RU
  • 6 Dept. Of Internal Medicine, I.M. Sechenov First Moscow State Medical University, Moscow/RU
  • 7 Oncology Department, RakFond, Moscow/RU
  • 8 Dept. Of Of Endocrinology, RUDN University, Moscow/RU


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5156


Metastatic renal cell carcinoma (mRCC) can cause sexual dysfunction as an adverse effect in male patients. Erectile dysfunction (ED) can also result from adverse effects of targeted therapy of mRCC, such as fatigue, pain, anorexia, asthenia or hypothyroidism. The objective of the study was to evaluate the rate of ED in a male population with mRCC.


One hundred thirty-two male patients with clear cell mRCC were enrolled. All patients were evaluated for erectile function with the 5-item version of the International Index of Erectile Function (IIEF-5) before and after the first cycle/month of the first-line targeted therapy with sunitinib, pazopanib, bevacizumab+IFN, sorafenib, or temsirolimus.


Median age was 59 years (range 43–67 years). 89 (67%) patients had at least one cardiovascular risk factor. At baseline, IIEF-5 mean score was 19 (SD, 2.6). Patients with 2 and more IMDC risk factors (39%) had a lower IIEF-5 mean score (14; SD, 3.3). 99 (75%) patients reported a negative change in their sexual life since the start of the targeted therapy. 35 (27%) patients had no sexual activity. After the first treatment cycle/month IIEF-5 mean score reduced to 8 (SD, 1.9), which was statistically significant (P < 0.001). The IIEF-5 scores were not associated with a type of anticancer treatment (P > 0.05).


Prospective evaluation in a large cohort of patients with mRCC revealed mild ED (19/25) in the treatment-naive male population and severe ED (8/25) after the first cycle/month of the first-line targeted therapy. Significant decrease in erectile function should be considered as a potential adverse event in male patients undergoing treatment of mRCC with targeted agents.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.